Compare RKT & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RKT | IMCR |
|---|---|---|
| Founded | 1985 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.0B | 1.7B |
| IPO Year | 2020 | 2021 |
| Metric | RKT | IMCR |
|---|---|---|
| Price | $18.71 | $36.52 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 15 | 9 |
| Target Price | $17.97 | ★ $67.00 |
| AVG Volume (30 Days) | ★ 26.9M | 338.1K |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | ★ 4.28% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,098,944,000.00 | $379,590,000.00 |
| Revenue This Year | $15.41 | $32.31 |
| Revenue Next Year | $72.61 | $10.50 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 41.68 | 28.11 |
| 52 Week Low | $10.06 | $23.15 |
| 52 Week High | $22.56 | $40.72 |
| Indicator | RKT | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 51.76 | 49.05 |
| Support Level | $18.58 | $35.35 |
| Resistance Level | $19.96 | $40.71 |
| Average True Range (ATR) | 0.79 | 1.82 |
| MACD | -0.05 | -0.45 |
| Stochastic Oscillator | 41.59 | 22.55 |
Rocket Companies is a financial services company that was originally founded as Rock Financial in 1985 and is currently based in Detroit. Rocket Companies offers a wide array of services and products but is best known for its Rocket Mortgage business. The company's mortgage lending operations are split between its direct-to-consumer lending, which sees borrowers accessing the company's lending arm directly through either its mobile app or website, and its partner network where mortgage brokers and other firms use Rocket's origination process to offer loans to their customers. The company has rapidly gained market share in recent years and will also be the largest mortgage servicer in the US following its acquisition of the Mr. Cooper Group.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.